Positive Phase III results for Indivior's RBP-7000 in schizophrenia

UK-based Indivior (LSE: INDV) today released encouraging top-line results from its Phase III clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia.

Indivior was formed late last year as a result of a demerger of the pharmaceutical business of consumer goods giant Reckitt Benckiser Group (LSE: RB).

In this pivotal study, both doses of RBP-7000 tested, 90mg and 120mg administered once-monthly, met the primary endpoint with statistically- and clinically-significant reductions in the symptoms of acute schizophrenia over an eight-week treatment period. Symptom reduction was measured using the change from baseline to end of treatment in the total Positive and Negative Syndrome Scale (PANSS) scores. RBP-7000 also met the key secondary endpoint with statistically significant improvements in the Clinical Global Impression-Severity of Illness (CGI-S) scale compared with placebo over the eight-week treatment period using change from baseline to end of treatment.